- Jubilant HollisterStier, a subsidiary of Jubilant Pharmova, has launched its third sterile injectable line at its Spokane, US facility, adding 50% capacity.
- The US$132 million investment supports complex injectable programs, enhances operational precision, and aims to double total sterile manufacturing capacity in Spokane.
Jubilant Pharmova Limited has expanded its North American contract manufacturing operations with the successful launch of a third sterile injectable line at its Spokane, Washington, facility. Operated by wholly owned subsidiary Jubilant HollisterStier (JHS), the new line began production with its inaugural batch, marking the start of revenue generation from the expansion.
The US$132 million investment forms part of a multi-phase growth strategy aimed at increasing domestic US sterile injectable capacity. The line incorporates advanced isolator technology to enhance sterility assurance, throughput, and operational precision, aligning with global regulatory standards. This addition brings a 50% increase in capacity at the Spokane facility.
“Launching our Third Line is more than a milestone for us—it’s a defining moment in Jubilant HollisterStier’s journey. With Third Line now operational and Fourth Line on the horizon, we are not just doubling our capacity, we’re building a future that will create hundreds of new jobs, strengthen the US pharmaceutical supply chain and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world.”
Chris Preti, CEO of CDMO Sterile Injectables at Jubilant HollisterStier, said:
JHS serves leading global pharmaceutical companies, with five of the top 20 firms as clients and a 92% customer retention rate. The company maintains compliance with regulatory authorities, including the US FDA, EMA, PMDA Japan, Health Canada, ANVISA Brazil, and other bodies across more than 140 countries.
